Processa Pharmaceuticals Ownership
| PCSA Stock | USD 1.16 0.18 18.37% |
Shares in Circulation | First Issued 2011-12-31 | Previous Quarter 3 M | Current Value 3.3 M | Avarage Shares Outstanding 5.1 M | Quarterly Volatility 5.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Processa |
Processa Stock Ownership Analysis
The company has price-to-book ratio of 1.01. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Processa Pharmaceuticals recorded a loss per share of 4.8. The entity last dividend was issued on the 23rd of December 2019. The firm had 1:20 split on the 22nd of January 2024. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. To find out more about Processa Pharmaceuticals contact the company at 443 776 3133 or learn more at https://www.processapharmaceuticals.com.Besides selling stocks to institutional investors, Processa Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Processa Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Processa Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Processa Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 9.0% of Processa Pharmaceuticals are currently held by insiders. Unlike Processa Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Processa Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Processa Pharmaceuticals' insider trades
Processa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Processa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Processa Pharmaceuticals backward and forwards among themselves. Processa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Processa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 24.4 K | Geode Capital Management, Llc | 2024-09-30 | 19.7 K | Tower Research Capital Llc | 2024-06-30 | 3 K | Wells Fargo & Co | 2024-06-30 | 154 | Main Street Group Ltd | 2024-06-30 | 100.0 | Hanson Mcclain Inc | 2024-09-30 | 85.0 | Bank Of America Corp | 2024-06-30 | 21.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Absolute Investment Management Llc | 2024-09-30 | 1.0 |
Processa Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Processa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Processa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Processa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Processa Pharmaceuticals Outstanding Bonds
Processa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Processa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Processa bonds can be classified according to their maturity, which is the date when Processa Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| PROCTER GAMBLE 645 Corp BondUS742718BH18 | View | |
| US742718AV11 Corp BondUS742718AV11 | View | |
| PROCTER GAMBLE 55 Corp BondUS742718CB39 | View | |
| PROCTER GAMBLE 555 Corp BondUS742718DF34 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.